To improve your customer experience, we are upgrading. On Thursday, 12 December, some areas of the GEO website, including members-only areas, may be intermittently unavailable. Thank you for your patience.
6.1 Executive Compensation in the Cannabis Industry: Silicon Valley on Steroids (Or on Something)
Executive and equity compensation in the cannabis sector has received little attention. The spotty adoption of legalization in the US combined with continued Federal treatment as a drug on par with heroin has caused business professionals - and banks - to stay away from the topic. But some extreme innovation is happening and many predict cannabis (fully legal in several countries) will be the next dot-com boom but this time with revenue and profit. These companies are being extremely creative (surprised?) in executive and equity compensation design and will likely ignore scrutiny of institutional investors and proxy advisers - their shares will be a "must buy" for serious investors and the implications for employee compensation and ownership are significant. This session provides a summary of current practices with the heavy IPO activity and focal point in Canada. Global equity professionals should be paying attention.